Analyst Ratings for [ZTS] Zoetis Inc. Class A

7/17/25	Downgrades	Outperform Mkt Perform	X
ZTS Zoetis Leerink Partners
$155
6/18/25	Downgrades	Buy Hold	X
ZTS Zoetis Stifel
$160
12/2/24	Initiated	Outperform	X
ZTS Zoetis Leerink Partners
$215
7/25/24	Initiated	Buy	X
ZTS Zoetis BTIG Research
$220
1/12/24	Reiterated	Buy	X
ZTS Zoetis Stifel
$195 $215
12/19/23	Resumed	Buy	X
ZTS Zoetis Jefferies
$230
12/7/23	Initiated	Outperform	X
ZTS Zoetis Exane BNP Paribas
$237
9/6/23	Initiated	Buy	X
ZTS Zoetis HSBC Securities
$230
7/12/22	Initiated	Overweight	X
ZTS Zoetis Piper Sandler
$205
11/18/21	Initiated	Overweight	X
ZTS Zoetis Morgan Stanley
$264
7/16/21	Downgrades	Outperform Mkt Perform	X
ZTS Zoetis Raymond James
3/8/21	Upgrades	Neutral Buy	X
ZTS Zoetis BofA Securities
$180
3/8/21	Upgrades	Mkt Perform Outperform	X
ZTS Zoetis Raymond James
$166
7/1/19	Downgrades	Buy Neutral	X
ZTS Zoetis BofA/Merrill
$111 $120
6/11/19	Initiated	Overweight	X
ZTS Zoetis Barclays
$120
5/3/19	Downgrades	Buy Hold	X
ZTS Zoetis Gabelli & Co
$108
3/20/19	Initiated	Hold	X
ZTS Zoetis SunTrust
3/4/19	Upgrades	Hold Buy	X
ZTS Zoetis Stifel
$97 $110
1/23/19	Initiated	Neutral	X
ZTS Zoetis UBS
$86
10/15/18	Upgrades	Neutral Overweight	X
ZTS Zoetis JP Morgan
8/22/18	Downgrades	Buy Hold	X
ZTS Zoetis Stifel
$95
8/3/18	Reiterated	Buy	X
ZTS Zoetis Stifel
$86 $95
4/19/18	Reiterated	Buy	X
ZTS Zoetis Citigroup
$85 $98
3/19/18	Downgrades	Overweight Eq-Weight	X
ZTS Zoetis Morgan Stanley
2/16/18	Reiterated	Buy	X
ZTS Zoetis Stifel
$84 $86

ZTS Zoetis Inc. Class A

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.